CYCLACEL PHARMACEUTICALS, INC.
Profile
Company Names
CYCLACEL PHARMACEUTICALS, INC.
Addresses
200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS, NJ 07922
200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS, NJ 07922
Phone Numbers
908-517-7330
(908) 517-7330
Entity Type:
CORPORATION
Industry:
BIOTECHNOLOGY
Year Incorporated:
> 5 years ago
State Incorporated:
DELAWARE
Total Amount Raised:
$36,298,338.00
Number of Funding Rounds:
7
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
7
2025-03-21
$1,000,000.00
$1,000,000.00
$0.00
Equity
6
2025-02-06
$0.00
$0.00
$0.00
Equity
5
2024-11-14
$2,062,112.00
$2,062,112.00
$0.00
Equity
4
2024-05-02
$8,000,000.00
$8,000,000.00
$0.00
Equity
3
2020-12-18
$7,000,000.00
$7,000,000.00
$0.00
Equity
2
2012-03-22
$3,036,000.00
$3,036,000.00
$0.00
Equity
1
2010-10-07
$15,200,226.00
$22,150,089.00
$6,949,863.00
Equity
People
First Name
Middle Name
Last Name
Titles
Related Companies
SAMUEL
L.
BARKER
DIRECTOR
AVRAHAM
BEN-TZVI
DIRECTOR
KENNETH
FERGUSON
DIRECTOR
DAVID
LAZAR
EXECUTIVE OFFICER
DAVID
NATAN
DIRECTOR
BRIAN
SCHWARTZ
DIRECTOR
FIRST CAPITAL HOLDINGS INC
| LEFT TACKLE LLC
| TLC HOLDINGS, LLC
| PEAK HOLDING CORP.
| PAPERBOARD PARENT, INC.
| BINARY EVENT NETWORK, INC.
| CO-INVESTMENT INCOME FUND, L.P. - NON-US SERIES
| CO-INVESTMENT INCOME FUND, L.P. - US TAXABLE SERIES
| PHOENIX QLS FUND, LTD.
| BELFRY FUND, L.P. - CORE PORTFOLIO
| CO-INVESTMENT INCOME FUND, L.P. - US TAX EXEMPT SERIES
| Q BLK APPRECIATION FUND II LLC
| Q-BLK APPRECIATION FUND LP
| RW FUND, LLC
| BRHF CUSTOM, LLC
| TAMUS ARS FUND LP
| WILLIAM FUND, LLC
| FQR ALTERNATIVES II, L.P.
| UNDISPUTED BOXING, INC.
| CAERUS DT FUND, LLC
| ORANGE 2015 DISLOCREDIT FUND, LP
| SONJ FUND ALIGNMENT + INCENTIVE REFORM, L.P.
| 1893 FUND, LLC
| BLACKROCK APPRECIATION STRATEGY FUND, LLC
| BLACKROCK CO-INVESTMENT FUND V, L.P. - US TAXABLE SERIES
| BELFRY FUND, L.P. - EP PORTFOLIO
| ORANGE 2015 DISLOCREDIT FUND, L.P.
| BLACKROCK CASCADE OPPORTUNITIES FUND, L.P.
| BLACKROCK MASTER HEDGE, L.P. - DIVERSIFIED SERIES
| BLACKROCK MASTER HEDGE, L.P. - OPPORTUNISTIC SERIES
| NEIL ENHANCED OPPORTUNITIES FUND, L.P.
| MALT ONSHORE FUND, L.P.
| GRAND RIVER ABSOLUTE RETURN FUND, LTD.
| BLACKROCK HFOF MRP, LTD.
| PIQUETTE FUND, LTD.
| HORSEBARN HILL INVESTMENT FUND, LTD.
| CYCLACEL PHARMACEUTICALS, INC.
| BLACKROCK BOWLING GREEN HEDGE FUND OF FUNDS, L.P.
| BLACKROCK BROADWAY FUND, L.P.
| ADQUICK, INC.
LLOYD
SEMS
DIRECTOR
ROBERT
SPIEGEL
DIRECTOR
FACE2FACE PARTNERS I, LLC
| PRE-IPO OPPORTUNITIES FUND LLC
| EDGE THERAPEUTICS, INC.
| NEXIMMUNE, INC.
| ACUITY OPPORTUNITIES FUND I LLC
| PINES AT WOODCREEK INVESTOR LLC
| ACUITY DATAMINR LLC
| ACUITY DATASTAX LLC
| ACUITY VARO BANK LLC
| ACUITY TANIUM LLC
| ACUITY TURO LLC
| ACUITY EPIRUS LLC
| ACUITY SPV VII LLC
| AYALA PHARMACEUTICALS, INC.
| RENOVORX, INC.
| CYCLACEL PHARMACEUTICALS, INC.
| DAWSON FOREST INVESTORS LLC
DAVID
U-PRICHARD
DIRECTOR
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2025-03-21
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2025-02-06
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2024-11-14
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2024-05-02
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2020-12-18
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2012-03-22
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2010-10-07
